IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Conditions: Esophageal Squamous Cell Carcinoma (ESCC); PD-1 Inhibitors Interventions: Drug: IBI110+Sintilimab Sponsors: The First Affiliated Hospital of Zhengzhou University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials